ライフサイエンスコーパス: die

1 zo1 to trigger extrusion of cells that later die.

2 invade are defective in nutrient import and die.

3 ferential wall thickenings, form a pore, and die.

4 nly in daughter cells that are programmed to die.

5 crotising enterocolitis, of whom 222 (48.1%) died.

6 is and/or tracheoplasty in our center, and 5 died.

7 s), 368 (9%) of the 4203 AREDS2 participants died.

8 013, 66 (86%) completed treatment and 4 (5%) died.

9 ED revisit, 4.7% were hospitalized, and 1.2% died.

10 To date, 9 patients have died.

11 men (30%) tested EVD positive; 6 of 13 (46%) died.

12 ccess dialysis died or were presumed to have died.

13 .3 years in 5,469 participants, 322 subjects died.

14 low-up time of 35.7 months, 190 patients had died.

15 Overall, 25 patients relapsed and 13 died.

16 Despite resuscitation efforts, the patient died.

17 low-up, 13% were hospitalized for HF and 27% died.

18 ) had <1,000 copies/ml; 20 participants (6%) died.

19 d slowly after the axonal trauma and neurons died.

20 (21%) of 393, and seven (2%) of 458 patients died.

21 s in the CABG group and 45% in the PCI group died.

22 ng follow-up (19 +/- 14 months), 65 patients died.

23 4 patients receiving tofacitinib monotherapy died.

24 individuals with ischemic events, 52 (10.9%) died.

25 g a 13-year follow-up, 33 (67%) participants died.

26 ian follow-up of 4.0 years, 340 participants died.

27 d an incident hip fracture, and 8998 (13.1%) died.

28 ion strategy for peak VO2 among patients who died.

29 d with relapsed or refractory disease and 12 died.

30 rst CV-related hospitalization, and 556 (6%) died.

31 rst separation attempt increases the risk of dying.

32 months (0.81, 0.66-0.99), and fewer infants died (0.63, 0.39-1.00).

33 Twenty-nine patients (31.5%) died (13.0 deaths/1,000 person-days of extracorporeal me

34 onal (50%) or national (<1%) liver; 60 (21%) died, 13 (4.5%) remained on the waitlist and nine (3.1%)

35 crotising enterocolitis, of whom 247 (46.5%) died (139 after laparotomy).

36 Eighteen patients died, 14 secondary to disease.

37 She died 16 years after transplantation.

38 emotherapy), at which point 415 patients had died (214 in the chemotherapy group and 201 in the chemo

39 r exit from study was higher in patients who died (3.0+/-8 versus 1.7+/-10 mm Hg; P=0.003).

40 edian follow-up of 6.8 years, 256 recipients died, 35 (13.7%) from recurrent cancer and 27 (10.5%) fr

41 Six children died (4% [95% CI, 1%-8%]), including 5 with comorbiditie

42 ears (range, 0.03-12.8 years), 1090 patients died (50.4%).

43 g and diarrhea, started palliative care, and died 60 hours after the fall.

44 QR 24.3 to not attainable), 131 patients had died: 70 (97%) of 72 in the vandetanib group and 61 (87%

45 enced an airflow decline; 138 patients (30%) died (78 azithromycin vs 60 placebo).

46 treatment failure or disease recurrence, or died (absolute risk difference -1.4%, 95% CI -7.0 to 4.3

47 (>/= 80 yr) had a significant higher risk of dying (adjusted odds ratio, 2.59; 95% CI, 1.66-4.03).

48 ese findings help to explain why CNS neurons die after axotomy, strongly suggest that A1 astrocytes c

49 interquartile range [IQR], 22-132); 16 (27%) died after a median of 12 (IQR, 0-24) days.

50 59 patients with HIV-tuberculosis, 16 (27%) died after a median of 12 days (interquartile range, 0-2

51 had neurosensory impairment, and 12 infants died after discharge.

52 ention clusters; 80 in control clusters), 77 died after the neonatal period and before 18 months (31

53 By the end of 2012, 5302 (6%) patients had died (all-cause mortality 118 per 10 000 person-years, 9

54 at health insurance saves lives: The odds of dying among the insured relative to the uninsured is 0.7

55 dly and continues to do so after guard cells die and collapse.

56 er homeostatic conditions, billions of cells die and must be swiftly cleared by phagocytes.

57 Cells with extensive DNA damage should die and not grow into malignancies.

58 cells, primarily alveolar type (AT) I cells, die and slough off, resulting in enhanced permeability.

59 any people have concerns about how they will die and the emphasis by medicine and society on interven

60 ile range, 3.5-6.0 years), 38 (15%) patients died and 106 (41%) either died or developed indication f

61 30 patients with >/=2 BCEs, 2 patients have died and 3 LQT3 patients underwent cardiac transplantati

62 f the 30,677 included patients, 1,649 (5.4%) died and 7,385 (24%) experienced the composite outcome (

63 During follow-up, 149 (21%) RTRs died and 82 (12%) developed graft failure.

64 er 24, 2016, a total of 1358 individuals had died and had brain autopsies that were approved by board

65 ontrolling sample shape by an added graphite die, and an energy efficient mass production of small an

66 Three of them died, and 1 is alive with hepatic metastasis.

67 subcohort of 1135 participants, of whom 203 died, and all remaining 390 participants who died throug

68 nd of follow-up, 36% of patients (93 of 256) died, and one underwent lung transplantation.

69 he embryo proper exhibited severe anemia and died around embryonic day 14.5.

70 it of the donation pathway from patients who died as a result of a devastating brain injury (possible

71 Twenty participants died as a result of ILD (crude rate, 2.7 per 10,000 pers

72 fluenza alone survived, 70% of comorbid mice died as a result of uncontrolled viral replication.

73 lack the small guanosine triphosphatase RSG1 die at embryonic day 12.5, with developmental abnormalit

74 Although host cells die at low extracellular pH, cancer cells resist, as the

75 king SHP2 in Col2alpha1-Cre-expressing cells die at mid-gestation.

76 Upon completion of these tasks, they neither die at the injury site nor are phagocytosed.

77 ss than 25% for the majority of patients who died at 1 year (n = 914).

78 e and chronic groups of Hyal2(-/-) mice that died at an average of 12 and 25 weeks respectively, were

79 Wnt1-Cre;Ift88fl/flpups died at birth due to severe craniofacial defects includi

80 Most (94%) died at home.

81 s (77.8%) had a less than 15% probability of dying at 1 year, yet this lower-risk end of the score ra

82 egia (HSP), a neurological disease involving dying-back degeneration of upper motor neurons.

83 23 (22%) patients died because of adverse events (mainly from sepsis, eigh

84 because of disease progression and two (13%) died because of an adverse event (one [7%] cerebrovascul

85 15 patients who died in the ceritinib group died because of disease progression and two (13%) died b

86 bronchial tissue obtained from subjects who died because of fatal asthma.

87 alphaII spectrin-deficient mice die before 1 month of age and have disrupted AIS and man

88 As Alpl-null mice die before weaning, we aimed to generate mouse models of

89 osed during the period from 1999 to 2011 and died before December 31, 2012.

90 Patients dying before unit discharge had 12.4% greater costs than

91 cohort of patients with childhood cancer who died between 2000 and 2012 in Ontario, Canada, was assem

92 group and 11 (11%) in the placebo group had died, but no death was judged to be related to treatment

93 ulture, the physiological fate of cells that die by apoptosis in vivo is their rapid recognition and

94 ional, prospective, observational study) and died by 2011.

95 Two women died by asphyxiation due to a tongue swelling.

96 One hundred three (8.7%) patients died by day 30 postadmission.

97 ; mean +/- SD age, 45 +/- 13 yr), with seven dying by 12-month follow-up.

98 duals with OCD had an increased risk of both dying by suicide (odds ratio (OR)=9.83 (95% confidence i

99 trol subjects, had an increased risk of both dying by suicide (odds ratio: 4.39; 95% confidence inter

100 f age in 272 HIV-infected infants who either died (cases) or survived (controls), and in 194 HIV-expo

101 ciency include a decreased capacity to clear dying cells and the establishment of a lupus-like autoim

102 Tissues have a natural capacity to replace dying cells and to heal wounds.

103 n (DAMP), released from ischemic tissues and dying cells which, when crystalized, is able to activate

104 roinflammatory properties to DNA released by dying cells, setting up a positive amplification loop be

105 , 1063 (19.7%) individuals after bevacizumab died compared with 1298 (12.1%) in the control group (P

106 ined with "mortality", "fatality", "death", "died", "deaths", or "CFR" for articles published in Engl

107 g to an ominous outcome in which the patient died despite specific treatment.

108 However, the extruder die did not have a measurable impact on the molecular we

109 atinocyte-specific Pnpla1-deficient neonates die due to epidermal permeability barrier defects with s

110 sis have approximately a 60% greater risk of dying due to alcohol-related causes compared with peers

111 -exposure due to glacier retreat, instead of dying (due to high rates of respiration supporting repai

112 plantation (15/142 versus 1/147; P<0.001) or die during study follow-up period (7 versus 0; P=0.007).

113 is was delayed or failed, and 50% of embryos died during development.

114 Almost all Armc5 knockout mice died during early embryonic development, around 6.5 and

115 om the trial 240 days after enrolment and 12 died during follow-up (five in the intervention group; s

116 Overall, 65 936 of the full sample died during follow-up, and 22 152 died from heart diseas

117 evere head or pelvic injuries, and those who died during hospitalization were excluded.

118 Approximately 14% of the ICC patients died during hospitalization.

119 ients who underwent randomization, 1 patient died during the 5-year follow-up period; 134 of the rema

120 escents who did not have their sex recorded, died during the index admission, had no valid discharge

121 12,123 children included for analysis, 1600 died during the median follow-up of 7.1 years.

122 % had coronary artery bypass surgery, and 3% died during the readmission.

123 Two (3%) patients in the 30 mg group died during the study (pulmonary artery thrombosis and c

124 11 participants died during the study follow-up period (six in the 9vHPV

125 major bleeding was recorded, and no patient died during the study.

126 23 (31%) patients died during the study; none of these deaths were deemed

127 d five (4%) of 113 in the chemotherapy group died during the treatment period (from the day of the fi

128 Twelve percent (n = 333) died during their hospital stay, 8.1% (n = 222) of patie

129 Of the 229 patients who died during their hospitalization, 149 (65.0%) had sepsi

130 Although the likelihood of dying during hospitalization was greater among patients

131 e suffer serious morbidity and 10,000 people die each year from the consequences associated with huma

132 at female mice inoculated with P. aeruginosa died earlier and showed slower bacterial clearance than

133 Induction of rhomboid in the dying enterocyte triggers activation of the EGF receptor

134 Millions of people die every year from diseases caused by exposure to outdo

135 s validated in the hippocampus of humans who died following status epilepticus.

136 h deep venous thrombosis; 28 patients (2.4%) died for cardiovascular causes.

137 Patients die from recurrent tumors that have become resistant to

138 cytokine concentrations were more likely to die from TBM.

139 om one patient in the chemotherapy group who died from a secondary tumour (head and neck anaplastic e

140 reasons for hospital admission of those who died from acute myocardial infarction.

141 Nine patients died from adverse events; five of these deaths were judg

142 rgan donor, the PHS donor was younger, male, died from anoxia, more likely to be HCV and antibody rea

143 erienced SBCE, 627 had a recurrence, and 237 died from breast cancer.

144 total of 4,952 men died, of which 1,637 men died from cardiovascular diseases (CVD), 2,122 from canc

145 and drought-tolerant species, and trees that died from competition.

146 A 9-month-old infant died from Ebola virus (EBOV) disease with unknown epidem

147 ull sample died during follow-up, and 22 152 died from heart disease.

148 BV or HCV infection, only 6 developed HCC or died from liver-related disease.

149 17 (5%) of 370 patients died from non-treatment-related adverse events associate

150 Within the study time, 36 patients died from NSCLC and 26 patients from other causes.

151 ts, 7,365 died of prostate cancer and 11,811 died from other causes during a median follow-up of 2.8

152 Whereas no patients died from PBC, the 5-year survival rate was 75%, as comp

153 e developing liver, and Gata4-mutant embryos died from subsequent liver hypoplasia and anemia.

154 nd prostate cancer (3,811 cases, 511 of whom died from the disease, compared with 2,980 controls-from

155 Carp maintained at 24 degrees C died from the infection, whereas those housed in multi-c

156 logeneic stem-cell transplantation and later died from transplantation-related complications.

157 vents associated with death, and one patient died from treatment-related adverse events (myositis in

158 g group; four (1%) versus two (<1%) patients died from treatment-related adverse events.

159 11 patients died from treatment-related causes (three in the twice-d

160 000-298 000) children younger than 15 years died from tuberculosis worldwide in 2015; 80% (191 000,

161 mo) after (90)Y TARE, and 41 patients (53%) died from tumor progression.

162 ual numbers of people who are developing and dying from cryptococcal meningitis.

163 old, a 26-fold, and a 18-fold higher risk of dying from myocardial infarction, heart failure, or stro

164 not seem to significantly affect the risk of dying from PCa.

165 r concordant causes of death (i.e., siblings dying from the same causes) but not for discordant cause

166 c enolase less than or equal to 17 mug/L who died had a cause of death other than hypoxic-ischemic en

167 For the primary analysis, patients who died had a value of 0 imputed for 24-week peak VO2.

168 (39%) of 90 people with a Mars1 endotype had died (hazard ratio [HR] vs all other endotypes 1.86 [95%

169 09 patients (49.3%) in the control group had died (hazard ratio [HR], 1.20; 95% CI, 1.01 to 1.42; P =

170 ve extreme physiologic dysfunction and often die if transplantation is not immediately available.

171 hy certain classes of neurons preferentially die in different neurodegenerative diseases.

172 Mediterranean shag, and Audouin's gull, that die in different types of fishing gears: longlines, gill

173 bout 420 000 cases annually, of whom 230 000 die in hospital.

174 Family members of patients who die in the ICU often remain with unanswered questions an

175 iably predict which individual patients will die in the next year.

176 who had the same condition, with one having died in childhood.

177 evere neurodevelopmental impairment and four died in early childhood.

178 At 24 months, 7 patients died in PVA group versus 22 in UPVA group.

179 13 (87%) of the 15 patients who died in the ceritinib group died because of disease prog

180 similar in the two study groups: 30 children died in the co-trimoxazole group, compared with 34 in th

181 Nearly 50% of newborns with the S187A mutant died in the first week due to failure to undergo the per

182 al of 2882 infants were admitted: 140 (4.9%) died in the hospital and 1405 infants were followed up a

183 Children who died in the hospital had higher levels of TNF-alpha, IL-

184 154 (60%) of 257 patients died in the intention-to-treat population: 74 (57%) of 1

185 Five women died in the placebo group and three died in the vaccine

186 umab group and 154 (81%) of 189 patients had died in the placebo group.

187 Jan 24, 2016), 307 (80%) of 382 patients had died in the tremelimumab group and 154 (81%) of 189 pati

188 ve women died in the placebo group and three died in the vaccine group.

189 l arm and 303 (5.2%) in the intervention arm died in their first 28 days of life (risk ratio 0.76, 95

190 c parameters, including the probabilities of dying in different fishing gears.

191 s associated with increased odds of patients dying in hospital following common surgical procedures.

192 tor predicted a more than 50% probability of dying in the next year for 52 of the 1661 patients who d

193 Overall, 11 patients died, including 5 (7.6%) in the SRL/MMF group and 6 (9.7

194 17 (19%) of 91 patients died, including seven because of disease progression.

195 lar cells are killed, but not when only OSNs die, indicating that HBCs are reserve stem cells that re

196 How cells decide which way to die is unclear.

197 Death and dying is a reality of the clinical context of the intens

198 n (AIE) and disaggregation-induced emission (DIE), MICE has not been systematically discussed to date

199 on was 4.6 years, and 16.5% (n = 390) either died (n = 35) or lost KPNC membership status (n = 355) w

200 Efficient removal of infected and dying neutrophils is required to protect the surrounding

201 53 patients in the overall safety population died; no deaths were related to treatment on study.

202 of 48 patients in the dose-escalation phase died (not determined to be related to nivolumab therapy)

203 ffects on mortality, as treated patients may die of a different cause exacerbated by the therapy.

204 ipients with PTM were 3 times more likely to die of cancer (pooled HR, 3.13; 95% CI, 2.29-4.27).

205 nosed with screen-detected breast cancer who die of causes other than breast cancer prior to clinical

206 diagnosed with acute myeloid leukemia (AML) die of their disease.

207 A third sibling also died of a similar presentation, but DNA was unavailable

208 ,947 person-years, 238 of 1226 (19.4%) women died of ASVD-related causes.

209 rly participant in the monotherapy group who died of cardiovascular failure 13 days after randomisati

210 fewer comorbid conditions than did those who died of causes other than SCD.

211 We aimed to describe children who died of IPD since PCV introduction in England and Wales.

212 e of the patients experienced metastases nor died of iris melanoma.

213 Three patients died of pneumonitis while in the study.

214 One patient died of progressive multifocal leukoencephalopathy.

215 Results Among 31,790 patients, 7,365 died of prostate cancer and 11,811 died from other cause

216 Twelve percent died of related causes and 10% presented superinfection

217 all patients with widespread chorioretinitis died of systemic complications of M. chimaera infection

218 have a higher risk of being hospitalized and dying of cardiovascular disease compared with the genera

219 C risk calculator estimated a probability of dying of less than 25% for the majority of patients who

220 Persons dying of opioid-related causes, particularly those who w

221 ,480 men in the cohort, a total of 4,952 men died, of which 1,637 men died from cardiovascular diseas

222 hospitalization, 25% (12/48) of patients had died, of whom only 1 initiated CAS; 67% (8/12) of these

223 tation models poorly represent recent forest die-off patterns.

224 nd die-off risk vary with body mass; and how die-off risk is affected by climate warming.

225 pidly lethal dehydration occurs; how EWL and die-off risk vary with body mass; and how die-off risk i

226 swan events manifest primarily as population die-offs and crashes (86%) rather than unexpected increa

227 cirumab and 43 (16%) of 265 assigned placebo died on treatment or within 30 days of discontinuation,

228 Unfortunately, the patient died one week after diagnosis.

229 Six participants died, one (2%) from the plasma plus standard care group

230 Two (1%) patients in the safety population died, one each in the deutetrabenazine 24 mg/day and 36

231 Four patients died, one who received immediate treatment (cardiac arre

232 n of plasma exchange and rituximab, but some die or acquire irreversible neurological deficits before

233 hildren with dilated cardiomyopathy, and 40% die or undergo transplantation.

234 38 (15%) patients died and 106 (41%) either died or developed indication for mitral valve surgery.

235 in 6 months of enrolment, the proportion who died or had a viral load of 400 copies/mL or higher at 1

236 In patients who died or survived within three months mean CE fraction wa

237 ed donor liver organ offers for children who died or were delisted compared with those who underwent

238 ransplant candidates in the US, children who died or were delisted received a median 1 pediatric live

239 f 140 children who could not access dialysis died or were presumed to have died.

240 system, which surveil their surroundings for dying or dead cells and efficiently clear them in a quie

241 receive at least one dose of study drug, who died, or who discontinued the study before the end of tr

242 Among 1025 subjects, 99 died over 8 years of follow-up.

243 distrust in the care that was provided to a dying parent.

244 ICU admissions for "palliative care of a dying patient" and "potential organ donation" increased

245 ust manage the dual obligation of caring for dying patients and their families while providing and/or

246 Reflecting the care of 70 dying patients, we conducted 208 semistructured qualitat

247 ir hospital stay, 8.1% (n = 222) of patients died postdischarge, and 155 (7.0%) were known to have su

248 clined, cell size increased, and nephrocytes died prematurely.

249 y, had a do-not-resuscitate order placed, or died prior to first extubation.

250 n of myriad forms of spirituality during the dying process in the ICU.

251 function as nonspecific effector cells that die quickly after performing antimicrobial functions.

252 s, and mouse and human intestinal organoids, died rapidly in response to TNF.

253 though the bulk of the bacterial population dies rapidly.

254 ss; however, the mechanisms by which neurons die remain elusive.

255 Participants (n = 145) completed a die-rolling task where they could misreport their outcom

256 he next year for 52 of the 1661 patients who died (sensitivity, 3.1%) and for 63 patients who lived a

257 Here, we show that mice deficient in GAS2L3 die shortly after birth because of heart failure.

258 -/-)) mice developed spontaneous tumors, and died significantly earlier than wild-type (Atf3(+/+)) mi

259 its from baseline (3/130 survivors; 9/28 who died) significantly increased the risk of death compared

260 lacking Nalcn in excitatory preBotC neurons died soon after birth; surviving mice developed apneas i

261 safe sleep environment, as most infants who die suddenly and unexpectedly do so in unsafe sleep envi

262 l screening in relatives of all subjects who died suddenly before 45 years of age.

263 igher likelihood to develop MCI, dementia or die than healthy controls).

264 te ownership had significantly lower odds of dying than women living in towns dominated by domestic p

265 However, after a patient with HF dies, their surviving spouse's risk of hospitalization a

266 hat the majority of CD4(+) T cells in tissue die through abortive infection, where the accumulation o

267 Trophozoites exposed to Ru(II) compounds die through an apoptotic pathway triggered by ROS produc

268 died, and all remaining 390 participants who died through mid-2013.

269 One patient in the placebo group died (unrelated to study treatment).

270 created two RP mouse models to test whether dying, untreated rods negatively impact treated, rescued

271 High numbers of monocytes died upon exposure to TKI concentrations similar to thos

272 opriate therapy (132 [38.5%] of 343 patients died vs 57 [60.6%] of 94; absolute difference 22.1% [95%

273 The proportion of persons who died was higher in the untreated group compared with eit

274 Patients who had SCD and those who did not die were younger and had fewer comorbid conditions than

275 nts had discontinued ruxolitinib (30 of whom died while on therapy).

276 Although individuals age and die with time, an animal species can continue indefinite

277 final clinical diagnoses were varied: 39.2% died with an MCI diagnosis, 46.8% with a dementia diagno

278 cs of children aged younger than 5 years who died with community-acquired RSV infection between Jan 1

279 a species obtained from brains of humans who died with confirmed AD elute at high molecular weight (H

280 Subjects who died with dementia and were without severe neurodegenera

281 who were linked to the GP surgery, 2 of whom died with MRSA bacteremia.

282 Within the cohort, 32 patients died with the leading cause of mortality cancer (25%), i

283 ths (range, 1 to 22 months), and one patient died with UMRD at 10 months.

284 erienced graft failure, and 70 patients (7%) died, with the most common cause of death being infectio

285 ctions, organ dysfunction, and at least half die within 1 year.

286 Without oxygen, most vertebrates die within minutes as they cannot meet cellular energy d

287 Of these, 75 (5.3%) died within 1 y during 1318 child-years of observation.

288 A total of 18 (22%) patients died within 14 days, including 12 (32%) in the CP-CRE gr

289 erapy, 68% of meningitis patients (23 of 34) died within 3 months.

290 nts admitted as weekend emergency admissions died within 30 days (p<0.0001).

291 9 of 73 (26%) patients in the overall cohort died within 30 days, but there was no significant differ

292 All recipients in WI-SCS group died within 6 hours after transplantation.

293 Two neonates born live in the ETU died within 8 days.

294 d CDI within 30 days after the index test or died within 90 days after the index toxin EIA date.

295 Three subjects (2%) died within the first 7 days, 107 (79%) exhibited rapid

296 mately 1 of 3 patients hospitalized with CAP dying within 1 year.

297 tibiotic treatment administered, the odds of dying within 14 days were more than 4 times greater for

298 039-1.294) increase in the odds of a patient dying within 30days of admission respectively.

299 D and dementia, respectively, and 26% to 33% died without either outcome.

300 boplatin, etoposide, and melphalan group had died without relapse by 5 years.